DVA·DaVita Inc.

DaVita Inc. is a leading provider of kidney dialysis services, primarily operating outpatient dialysis centers and offering a comprehensive suite of kidney care solutions in the United States. As a key player in the Healthcare sector's Medical Care Facilities industry, DaVita's business model centers on delivering essential treatments and managing patient health through various care options and supporting clinical laboratories. The company has a long-standing presence, established in 1994 and headquartered in Denver, Colorado. In its most recent reported quarters, DaVita demonstrated a mixed performance. For Q1 2026, the company reported actual EPS of $2.87 against an estimate of $2.33, and actual revenue of $3.416 billion against an estimate of $3.356 billion, indicating a beat on both metrics. This followed Q3 2025, where actual EPS was $2.51, missing the estimate of $3.17, though revenue of $3.420 billion exceeded the prior quarter's revenue. Prior to that, Q2 2025 saw actual EPS of $2.95, beating the estimate of $2.75, with revenue also showing an increase. The company's earnings have shown some volatility, with a beat in Q1 2026 and Q2 2025, but a miss in Q3 2025. Revenue has generally trended upwards over the reported periods, with Q1 2026 revenue marking a new high. Recent news highlights a strong Q1 performance with raised full-year guidance and positive analyst sentiment, including a significant price target increase and a "Strong Buy" rating from Zacks. However, other reports indicate ongoing concerns about stagnant treatment volumes over the past two years, necessitating price increases for revenue growth and projecting a slowdown in demand. A declining free cash flow margin over five years also points to increasing capital intensity. Investors will be watching for continued operational improvements, the impact of technological investments, and future volume trends in the upcoming quarters.